Please provide your email address to receive an email when new articles are posted on . Adults with congenital adrenal hyperplasia receiving an oral corticotropin-releasing factor type 1 receptor ...

Management of classic congenital adrenal hyperplasia (CAH) can be a lifelong balancing act, but the most feared life-threatening complication is an acute adrenal insufficiency, also known as an ...

Please provide your email address to receive an email when new articles are posted on . The FDA approved crinecerfont to treat patients with congenital adrenal hyperplasia. The drug directly reduces ...

BOSTON -- Investigational crinecerfont reduced the need for glucocorticoids in adults and kids with congenital adrenal hyperplasia (CAH), two phase III trials found. In the adult trial of 182 patients ...

Congenital adrenal hyperplasia (CAH) is a rare genetic condition present from birth. A person with CAH lacks one of the enzymes needed for their adrenal glands to work correctly. Sitting above the ...

CRENESSITY, the first new treatment available in 70 years to the classic congenital adrenal hyperplasia (CAH) community, offers a paradigm-shifting treatment approach FDA approval supported by data ...

With the expanded indication, Efmody is now indicated for both adrenal insufficiency and congenital adrenal hyperplasia in ...

SAN DIEGO, Jan. 21, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced publication of a classic congenital adrenal hyperplasia (CAH)-focused supplement in The Journal of ...

SAN DIEGO, July 15, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NBIX) (Nasdaq: NBIX) today announced results from a new analysis using real-world data from CAHtalog ®, a comprehensive registry ...

Nonclassical congenital adrenal hyperplasia (NCAH) can lead to the production of excess male hormones. It is usually a mild condition and often doesn’t need to be treated if there are no symptoms.